Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of co-administration of JW0108 and C2407 in dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• C2407
• JW0108

Snippet

Sponsor: JW Pharmaceutical | Conditions: Dyslipidemia | Phase 3 | Status: COMPLETED